Roots Analysis has done a detailed study on Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 350+ page report, which features 150+ figures and 200+ tables, please visit this link

Key Market Insights
 Presently, nearly 300 non-invasive diagnostic tests, designed for the detection of various types of cancers, are either already available in the market or under development across the world
 Several modern diagnostic tests claim to be capable of offering results in relatively short time periods, thereby, facilitating early diagnosis that is particularly beneficial in the treatment of different types of cancers
 Over time, big pharma players have initiated product development programs, having invested significant capital, time and effort, on non-invasive diagnostic solutions for use across different oncological indications
 Investors, having realized the untapped opportunity within this emerging segment of the cancer diagnostics market, have invested over USD 3 billion across 120 instances in the period between 2015 and 2019
 The growing interest in this field is also reflected in the partnership activity; deals inked in the recent past are focused on a diverse range of tumor markers, involving both international and indigenous stakeholders
 The projected future opportunity is anticipated to be driven by increasing patient population and distributed across various disease indications and application areas across key geographies
 These tests are capable of detecting diverse tumor markers that cater to the needs of different stakeholders; in fact, opinions of industry experts confirm the vast potential of liquid biopsies in disease diagnosis / monitoring

For more information, please visit https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Cancer Statistics and Burden of the Disease
3.3. Importance of Early Cancer Detection
3.4. Cancer Screening and Diagnosis

3.5. Conventional Invasive Cancer Diagnostic Tests
3.5.1. Biopsy
3.5.1.1. Fine Needle Aspiration Biopsy
3.5.1.2. Core Needle Biopsy
3.5.1.3. Vacuum-Assisted Biopsy
3.5.1.4. Image-Guided Biopsy
Press Release: Variation 2 (Format 3)

3.5.1.5. Sentinel Node Biopsy
3.5.1.6. Surgical Biopsy
3.5.1.7. Endoscopic Biopsy
3.5.1.8. Bone Marrow Biopsy
3.5.2. Endoscopy

3.6. Need for Non-Invasive Approaches

3.7. Liquid Biopsy: Diagnosing Circulating Biomarkers
3.7.1. Circulating Tumor Cells
3.7.2. Circulating Tumor DNA
3.7.3. Exosomes

3.8. Costs and Benefits Associated with Liquid Biopsy and Non-Invasive Tests
3.9. Emerging Trends in Intellectual Property Related to Non-Invasive Cancer Diagnostics
3.10. Challenges Associated with Non-Invasive Cancer Diagnostics
3.11. Future Perspectives

4. NON-INVASIVE CANCER SCREENING AND DIAGNOSIS
4.1. Chapter Overview
4.2. Diagnostic Imaging
4.2.1. Magnetic Resonance Imaging (MRI)
4.2.2. Mammography
4.2.3. Bone Scan
4.2.4. Computerized Tomography (CT) Scan
4.2.5. Integrated Positron Emission Tomography (PET)-CT Scan
4.2.6. Ultrasound
4.2.7. X-ray Radiography (Barium Enema)

4.3. Screening Assays
4.3.1. Circulating Tumor Marker Test
4.3.2. Digital Rectal Exam (DRE)
4.3.3. Fecal Occult Blood Test (FOBT)
4.3.4. Multigated Acquisition (MUGA) Scan
4.3.5. Papanicolaou Test and Human Papilloma Virus Test

4.4. Advanced Non-Invasive Approaches
4.4.1. Cytogenetic / Gene Expression Studies
4.4.2. Molecular Signature-based Non-Invasive Methods
4.4.3. Saliva-based Oral Cancer Diagnostics
4.4.4. Vital Staining
4.4.5. Optical Biopsy
4.4.6. Other Diagnostic Techniques

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Liquid Biopsy Products: List of Developers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size and Geographical Location
5.2.3. Leading Players
5.2.4. Analysis by Geography

5.3. Liquid Biopsy Products: List of Available / Under Development Products
5.3.1. Analysis by Status of Development
5.3.2. Analysis by Type of Product
5.3.3. Analysis by Application Area
Press Release: Variation 2 (Format 3)

5.3.4. Analysis by Target Cancer Indication
5.3.5. Analysis by Type of Tumor Marker
5.3.6. Analysis by End User
5.3.7. Analysis by Turnaround Time

5.4. Liquid Biopsy Products: List of Other Products, Kits and Consumables
5.5. Liquid Biopsy Products: List of Contract Service Providers

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Amoy Diagnostics
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Liquid Biopsy Product Portfolio
6.2.4. Recent Developments and Future Outlook

6.3. DiaCarta
6.3.1. Company Overview
6.3.2. Liquid Biopsy Product Portfolio
6.3.3. Recent Developments and Future Outlook

6.4. HaploX
6.4.1. Company Overview
6.4.2. Liquid Biopsy Product Portfolio
6.4.3. Recent Developments and Future Outlook

6.5. NeoGenomics
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Liquid Biopsy Product Portfolio
6.5.4. Recent Developments and Future Outlook

6.6. QIAGEN
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Liquid Biopsy Product Portfolio
6.6.4. Recent Developments and Future Outlook

6.7. Swift Biosciences
6.7.1. Company Overview
6.7.2. Liquid Biopsy Product Portfolio
6.7.3. Recent Developments and Future Outlook

6.8. Sysmex Inostics
6.8.1. Company Overview
6.8.2. Liquid Biopsy Product Portfolio
6.8.3. Recent Developments and Future Outlook

6.9. Thermo Fisher Scientific
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Liquid Biopsy Product Portfolio
6.9.4. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
Press Release: Variation 2 (Format 3)

7.2. Partnership Models
7.3. List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Type of Tumor Marker
7.3.4. Analysis by Target Cancer Indication
7.3.5. Analysis by Type of Partner
7.3.6. Most Active Players: Analysis by Number of Partnerships
7.3.7. Regional Analysis
7.3.7.1. Intercontinental and Intracontinental Agreements

8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Types of Funding

8.3. List of Funding and Investment Instances
8.3.1. Analysis by Number of Funding Instances
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Analysis by Target Cancer Indication
8.3.5. Analysis by Type of Tumor Marker
8.3.6. Most Active Players: Analysis by Amount Invested
8.3.7. Most Active Investors: Analysis by Number of Funding Instances
8.3.8. Regional Analysis by Amount Invested

8.4. Concluding Remarks

9. LIQUID BIOPSY: INITIATIVES OF BIG PHARMA PLAYERS
9.1. Chapter Overview
9.2. Top Pharmaceutical Companies
9.2.1. Analysis by Status of Development
9.2.2. Analysis by Type of Tumor Marker
9.2.3. Analysis by Application Area
9.2.4. Analysis by Target Cancer Indication

10. KEY ACQUISITION TARGETS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Scoring Criteria and Key Assumptions
10.4. Potential Strategic Acquisition Targets in North America
10.5. Potential Strategic Acquisition Targets in Europe
10.6. Potential Strategic Acquisition Targets in Asia-Pacific / Rest of the World
10.7. Concluding Remarks

11. OTHER NON-INVASIVE CANCER DIAGNOSTICS
11.1. Chapter Overview
11.2. Non-Blood-based Biomarker Detection Tests
11.3. FOBT and Fecal Immunochemical Tests (FIT)
11.4. Pigmented Lesion Assays
11.5. Stool DNA (sDNA)-based Tests
11.6. Volatile Organic Compound (VOC) Detection Tests
11.7. Other Non-Invasive Cancer Diagnostics: Market Landscape

12. MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
Press Release: Variation 2 (Format 3)

12.3. Global Non-Invasive Cancer Diagnostics Market, 2019-2030

12.3.1. Global Liquid Biopsy Market, 2019-2030
12.3.1.1. Global Liquid Biopsy Market: Distribution by Application Area, 2019-2030
12.3.1.1.1. Global Liquid Biopsy Market for Early Diagnosis, 2019-2030
12.3.1.1.2. Global Liquid Biopsy Market for Patient Monitoring, 2019-2030
12.3.1.1.3. Global Liquid Biopsy Market for Recurrence Monitoring, 2019-2030

12.3.1.2. Global Liquid Biopsy Market: Distribution by Target Cancer Indication, 2019-2030
12.3.1.2.1. Global Liquid Biopsy Market for Breast Cancer, 2019-2030
12.3.1.2.2. Global Liquid Biopsy Market for Lung Cancer, 2019-2030
12.3.1.2.3. Global Liquid Biopsy Market for Colorectal Cancer, 2019-2030
12.3.1.2.4. Global Liquid Biopsy Market for Prostate Cancer, 2019-2030
12.3.1.2.5. Global Liquid Biopsy Market for Bladder Cancer, 2019-2030
12.3.1.2.6. Global Liquid Biopsy Market for Melanoma, 2019-2030
12.3.1.2.7. Global Liquid Biopsy Market for Gastric Cancer, 2019-2030
12.3.1.2.8. Global Liquid Biopsy Market for Pancreatic Cancer, 2019-2030
12.3.1.2.9. Global Liquid Biopsy Market for Ovarian Cancer, 2019-2030

12.3.1.3. Global Liquid Biopsy Market: Distribution by Type of Tumor Marker, 2019-2030
12.3.1.3.1. Global Liquid Biopsy Market for ctDNA, 2019-2030
12.3.1.3.2. Global Liquid Biopsy Market for cfDNA, 2019-2030
12.3.1.3.3. Global Liquid Biopsy Market for CTCs, 2019-2030
12.3.1.3.4. Global Liquid Biopsy Market for Exosomes, 2019-2030
12.3.1.3.5. Global Liquid Biopsy Market for Other Tumor Markers, 2019-2030

12.3.1.4. Global Liquid Biopsy Market: Distribution by Type of Analyte, 2019-2030
12.3.1.4.1. Global Liquid Biopsy Market for Blood, 2019-2030
12.3.1.4.2. Global Liquid Biopsy Market for Other Body Fluids, 2019-2030 (USD Billion)

12.3.1.5. Global Liquid Biopsy Market: Distribution by End User, 2019-2030
12.3.1.5.1. Global Liquid Biopsy Market for Hospitals, 2019-2030
12.3.1.5.2. Global Liquid Biopsy Market for Research Institutes, 2019-2030
12.3.1.5.3. Global Liquid Biopsy Market for Other End Users, 2019-2030

12.3.1.6. Global Liquid Biopsy Market: Distribution by Geography, 2019-2030
12.3.1.6.1. Liquid Biopsy Market in the US, 2019-2030
12.3.1.6.2. Liquid Biopsy Market in the UK, 2019-2030
12.3.1.6.3. Liquid Biopsy Market in Germany, 2019-2030
12.3.1.6.4. Liquid Biopsy Market in France, 2019-2030
12.3.1.6.5. Liquid Biopsy Market in Italy, 2019-2030
12.3.1.6.6. Liquid Biopsy Market in Spain, 2019-2030
12.3.1.6.7. Liquid Biopsy Market in Japan, 2019-2030
12.3.1.6.8. Liquid Biopsy Market in China, 2019-2030
12.3.1.6.9. Liquid Biopsy Market in India, 2019-2030
12.3.1.6.10. Liquid Biopsy Market in Australia, 2019-2030

12.3.2. Other Non-Invasive Cancer Diagnostics Market Forecast, 2019-2030

13. SURVEY INSIGHTS
13.1. Chapter Overview
13.2. Company Specifics of Respondents
13.3. Designation of Respondents
13.4. Type of Product Portfolio
13.5. Types of Products / Services Offered
13.6. Application Area
Press Release: Variation 2 (Format 3)

13.7. Status of Development of the Products
13.8. Likely Market Size

14. CONCLUSION
14.1. Timely Disease Detection and Subsequent Monitoring are Critical Elements of Patient Care
in the Field of Oncology
14.2. Introduction of Sophisticated Molecular Diagnostics has Facilitated Better Cancer
Management
14.3. Liquid Biopsy has Emerged as a Reliable Alternative to the Invasive Methods of Diagnosis
14.4. The Versatile and Patient Friendly Nature of these Diagnostic Tools Cater to a Wide Range
of Applications
14.5. The Interest is Gradually Rising with Participation of Several Start-ups Across Different
Geographies
14.6. In Addition to Liquid Biopsy, Development of Other Non-Invasive Tests will Further
Strengthen the Ongoing Innovation
14.7. Rising Venture Capital Support is Indicative of a Lucrative Future Potential
14.8. Primarily Led by Liquid Biopsy, the Non-Invasive Cancer Diagnostics Market has Emerged
as a Multi-Billion Dollar Market

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Interview Transcript: Shibichakravarthy Kannan, Founder & Chief Executive Officer,
Theranosis Life Sciences
15.3. Interview Transcript: Anton Iliuk, President and Chief Technology Officer, Tymora Analytical
Operations
15.4. Interview Transcript: Peter French, Strategic Technology Advisor, Sienna Cancer
Diagnostics
15.5. Interview Transcript: Joachim Fluhrer, Founder and Medical Director, Genostics
15.6. Interview Transcript: Brad Walsh, Chief Executive Officer, Minomic International
15.7. Interview Transcript: Catalina Vasquez, Chief Operating Officer, Nanostics
15.8. Interview Transcript: Burkhard Jansen, Chief Medical Officer, DermTech
15.9. Interview Transcript: Frank Szczepanski, President and CEO, IVDiagnostics
15.10. Interview Transcript: Riccardo Razzini, Sales and Marketing Manager, LCM Genect
15.11. Interview Transcript: Nathalie Bernard, Marketing Director, OncoDNA
15.12. Interview Transcript: Abizar Lakdawalla, Founder, Proxeom
15.13. Interview Transcript: Mark Li, CEO, Resolution Bioscience
15.14. Interview Transcript: Christer Ericsson, Chief Scientific Officer, iCellate Medical
15.15. Interview Transcript: Philippe Nore, CEO and Co-founder, MiNDERA
15.16. Interview Transcript: Jake Micallef, Chief Scientific Officer, VolitionRx

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]